Background:Clear cell renal cell carcinoma(ccRCC)is an aggressive malignancy associated with limited treatment options and poor prognosis.Emerging studies suggest that the actin-regulating protein actin-related protei...Background:Clear cell renal cell carcinoma(ccRCC)is an aggressive malignancy associated with limited treatment options and poor prognosis.Emerging studies suggest that the actin-regulating protein actin-related protein 2/3 complex subunit 1B(ARPC1B),a key regulatory protein within the actin cytoskeleton,could play a pivotal role in ccRCC progression.The current study aimed to uncover the biological functions of ARPC1B and the molecular mechanisms driving its effects in ccRCC.Methods:ARPC1B expression and prognostic implications were analyzed using data sourced from the Gene Expression Profiling Interactive Analysis(GEPIA)platform,immunohistochemical(IHC)staining on 150 tumor samples along with 30 corresponding normal tissues,and Western blotting(WB)analyses across multiple ccRCC-derived cell lines.Functional assays assessing cell proliferation,colony formation capability,migration,invasion,and in vivo tumorigenicity were conducted following either ARPC1B suppression or upregulation.Additionally,WB analysis was utilized to evaluate proteins linked to epithelial-to-mesenchymal transition(EMT)and the Wnt/β-catenin pathway.Results:The findings revealed a substantial elevation of ARPC1B in ccRCC tissues and cell lines,significantly associated with advanced TNM stages,higher Fuhrman grades,and reduced overall survival(OS)(p<0.001).Multivariate statistical analysis identified ARPC1B as a standalone prognostic factor.Silencing ARPC1B notably impaired ccRCC cellular activities,and tumorigenesis in animalmodels,whereas augmented ARPC1B expression enhanced these malignant phenotypes.Mechanistically,downregulation of ARPC1B suppressed Wnt/β-catenin signaling and disrupted EMT,indicated by reducedβ-catenin,c-Myc,cyclin D1,and ZEB-1 levels,and concurrently increased E-cadherin expression.Additionally,reactivation of theWnt/β-catenin pathway partly reversed the inhibitory effects of ARPC1B depletion on tumor growth and invasiveness.Conclusions:ARPC1B emerges as an essential oncogenic factor in ccRCC by stimulating EMT and activating the Wnt/β-catenin pathway,ultimately enhancing tumor aggressiveness and metastatic potential.Thus,targeting ARPC1B represents a promising therapeutic strategy,warranting further exploration in ccRCC management.展开更多
采用铜模吸铸制备了厚度为0.8 mm,成分为Nd9Fe81-x-yTi4C2BxNby(x=11,13,15;y=0,4)的Nd2Fe14B/Fe3B型纳米复合永磁合金块体样品,研究了添加Nb对合金铸态组织及其晶化行为的影响,并测试了其磁性能。结果表明:在合金中添加4%(原子分数)Nb...采用铜模吸铸制备了厚度为0.8 mm,成分为Nd9Fe81-x-yTi4C2BxNby(x=11,13,15;y=0,4)的Nd2Fe14B/Fe3B型纳米复合永磁合金块体样品,研究了添加Nb对合金铸态组织及其晶化行为的影响,并测试了其磁性能。结果表明:在合金中添加4%(原子分数)Nb元素,不仅能抑制吸铸样品表面Nd2Fe23B3软磁性相、Nd1.1Fe4B4非磁性相和未知相的形成,导致Nd2Fe14B,Fe3B和α-Fe相的相对量增加,而且促使样品内部在非晶基体上形成了少量的Nd2Fe14B和α-Fe,Fe3B纳米晶。添加了Nb的合金吸铸样品表现出一定的硬磁性,其中Nd9Fe66Ti4C2B15Nb4吸铸样品具有最高的矫顽力(Hci=116.66 k A·m-1);添加4%(原子分数)Nb使得合金在晶化过程中由原来的异相同温一步晶化转变为两步晶化,且初始晶化温度Tx均明显降低,两个放热峰的ΔTpx均增大。展开更多
文摘Background:Clear cell renal cell carcinoma(ccRCC)is an aggressive malignancy associated with limited treatment options and poor prognosis.Emerging studies suggest that the actin-regulating protein actin-related protein 2/3 complex subunit 1B(ARPC1B),a key regulatory protein within the actin cytoskeleton,could play a pivotal role in ccRCC progression.The current study aimed to uncover the biological functions of ARPC1B and the molecular mechanisms driving its effects in ccRCC.Methods:ARPC1B expression and prognostic implications were analyzed using data sourced from the Gene Expression Profiling Interactive Analysis(GEPIA)platform,immunohistochemical(IHC)staining on 150 tumor samples along with 30 corresponding normal tissues,and Western blotting(WB)analyses across multiple ccRCC-derived cell lines.Functional assays assessing cell proliferation,colony formation capability,migration,invasion,and in vivo tumorigenicity were conducted following either ARPC1B suppression or upregulation.Additionally,WB analysis was utilized to evaluate proteins linked to epithelial-to-mesenchymal transition(EMT)and the Wnt/β-catenin pathway.Results:The findings revealed a substantial elevation of ARPC1B in ccRCC tissues and cell lines,significantly associated with advanced TNM stages,higher Fuhrman grades,and reduced overall survival(OS)(p<0.001).Multivariate statistical analysis identified ARPC1B as a standalone prognostic factor.Silencing ARPC1B notably impaired ccRCC cellular activities,and tumorigenesis in animalmodels,whereas augmented ARPC1B expression enhanced these malignant phenotypes.Mechanistically,downregulation of ARPC1B suppressed Wnt/β-catenin signaling and disrupted EMT,indicated by reducedβ-catenin,c-Myc,cyclin D1,and ZEB-1 levels,and concurrently increased E-cadherin expression.Additionally,reactivation of theWnt/β-catenin pathway partly reversed the inhibitory effects of ARPC1B depletion on tumor growth and invasiveness.Conclusions:ARPC1B emerges as an essential oncogenic factor in ccRCC by stimulating EMT and activating the Wnt/β-catenin pathway,ultimately enhancing tumor aggressiveness and metastatic potential.Thus,targeting ARPC1B represents a promising therapeutic strategy,warranting further exploration in ccRCC management.
文摘采用铜模吸铸制备了厚度为0.8 mm,成分为Nd9Fe81-x-yTi4C2BxNby(x=11,13,15;y=0,4)的Nd2Fe14B/Fe3B型纳米复合永磁合金块体样品,研究了添加Nb对合金铸态组织及其晶化行为的影响,并测试了其磁性能。结果表明:在合金中添加4%(原子分数)Nb元素,不仅能抑制吸铸样品表面Nd2Fe23B3软磁性相、Nd1.1Fe4B4非磁性相和未知相的形成,导致Nd2Fe14B,Fe3B和α-Fe相的相对量增加,而且促使样品内部在非晶基体上形成了少量的Nd2Fe14B和α-Fe,Fe3B纳米晶。添加了Nb的合金吸铸样品表现出一定的硬磁性,其中Nd9Fe66Ti4C2B15Nb4吸铸样品具有最高的矫顽力(Hci=116.66 k A·m-1);添加4%(原子分数)Nb使得合金在晶化过程中由原来的异相同温一步晶化转变为两步晶化,且初始晶化温度Tx均明显降低,两个放热峰的ΔTpx均增大。
